penpulimab + doxorubicin + vinblastine + dacarbazine

Penpulimab + doxorubicin + vinblastine + dacarbazine is a combination regimen consisting of four distinct antineoplastic agents. Penpulimab is a humanized IgG1 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor activity[4][5]. Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cells. Vinblastine is a vinca alkaloid that disrupts microtubule formation, inhibiting mitosis. Dacarbazine is an alkylating agent that induces DNA damage through methylation. This combination has been used in oncology for synergistic cytotoxic and immunotherapeutic effects, though penpulimab has not been widely reported in clinical use with this specific chemotherapy backbone; it represents an investigational or off-label regimen.

Brand names

Anniko

Other names

Penpulimab + AVDPianzumab + AVDAK105 + AVD